Pcn99 - Evaluating the Increasing Strain of Immunotherapies (Pd-1/Pd-L1) on Public Healthcare Systems in T5 + Us

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.181
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Immunotherapies Based on PD-1/PD-L1 Pathway Inhibitors in Ovarian Cancer Treatment

Clinical and Experimental Immunology
AllergyImmunology
2019English

Macrophage PD-L1 Strikes Back: PD-1/PD-L1 Interaction Drives Macrophages Toward Regulatory Subsets

Advances in Bioscience and Biotechnology
2013English

The Immunoinhibitory PD-1/PD-L1 Pathway in Inflammatory Blood Vessel Disease

Journal of Leukocyte Biology
AllergyImmunologyCell Biology
2017English

The Role of PD-1/PD-L1 Signaling Pathway in Antitumor Immune Response

Klinicka Onkologie
Oncology
2016English

Oncolytic Virus and PD-1/PD-L1 Blockade Combination Therapy

Oncolytic Virotherapy
2018English

Pcn232 - Variation in Access to Pd-1 Immunotherapies in Europe

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

High-Affinity PD-1 Molecules Deliver Improved Interaction With PD-L1 and PD-L2

Cancer Science
Cancer ResearchMedicineOncology
2018English

The Importance of the PD-1/PD-L1 Pathway at the Maternal-Fetal Interface

BMC Pregnancy and Childbirth
GynecologyObstetrics
2019English

Blocking the PD-1/PD-L1 Pathway in Glioma: A Potential New Treatment Strategy

Journal of Hematology and Oncology
Cancer ResearchOncologyHematologyMolecular Biology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy